CTRI/2021/04/033110尚未招募未知
Optimizing duration of corticosteroid therapy in adult steroid sensitive nephrotic syndrome due to primary minimal change disease(MCD) /focal segmental glomerulosclerosis(FSGS) â?? a prospective open label randomized controlled trial(RCT)
Funding applied for0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adult (>=18 years) patients with NS due to primary MCD/FSGS who achieved remission (SSNS) when treated for the first time with oral prednisolone 1mg/kg/day for at-least 4 weeks and a maximum duration of 16 weeks.
排除标准
- •1) eGFR <60ml/min per 1.73 m2
- •(2) Nephrotic range proteinuria without nephrotic syndrome
- •(3) Presence of other concomitant diseases on kidney biopsy
- •(4) Secondary cause of MCD and FSGS
- •(5) Concomitant systemic disease like diabetes, hepatitis B or C or HIV infection
- •(6) Prior treatment with immunosuppression for NS
- •(7) Prior treatment with immunosuppression for any other indication in the past 6 months
- •(8) Patients who have concomitantly received other immunosuppressive drugs in addition to prednisolone for initial treatment of the NS
研究者
相似试验
尚未招募
不适用
Aproach to optimize the dose of contrasut medicum considering patient's blood flow on CTA.JPRN-UMIN000027046Ryukyu unversity hospital50
尚未招募
不适用
A clinical study to determine the optimal dose of WIN-1001X by evaluating its efficacy and safety in patients with early Parkinson’s diseaseDiseases of the nervous systemKCT0004536Medihelpline188
尚未招募
3 期
Deciding the duration of blood thinners following acute venous thromboembolism (VTE) by assessing residual venous thrombosis by ultrasound scaCTRI/2023/06/053767Indian Council of Medical Research
进行中（未招募）
不适用
Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients - Hip 1pre-cirrhotic chronic hepatitis B virus (HBV) infectionEUCTR2005-005849-19-GBSouthampton University Hospitals NHS Trust36
进行中（未招募）
1 期
A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe hay fever in patients suffering from allergic inflammation of the conjunctiva which is caused by grass pollen allergens.This clinical trial aims to evaluate a conjunctival provocation test (CPT) with the IMP gpCPT+ for the assessment and grading of grass pollen allergic rhinoconjunctivitis. Thus, a diagnostic solution will be tested and not medical condition or disease. Patients will be included in this trial who are suffering from grass pollen allergic rhinoconjunctivitis.MedDRA version: 20.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853EUCTR2017-004616-19-DEASIT biotech S.A.76